EARNINGS: Merck beats on Keytruda, Januvia/Janumet revenue, misses on Remicade, Zepatier

Yahoo Finance's Jared Blikre and Alexis Christoforous break down the latest market action after the drugmaker reported Q1 2018 earnings.

What to Read Next